Loading
Life sciences · Journal article
Annals of Surgical Oncology · October 20, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Background Immune checkpoint inhibitors (ICIs) have limited efficacy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer, and the mechanisms underlying immune resistance remain unclear. The androgen receptor gene ( AR ), expressed in a substantial proportion of ER-positive tumors, has been implicated in tumor biology; however, its role in the tumor immune microenvironment and immunotherapy response is not well understood. Methods We investigated the association between AR expression, transcriptome-derived immune cell-associated signatures, and response to ICIs in 4046 patients with breast cancer across five cohorts with bulk transcriptomic data and two cohorts with single-cell transcriptomic data. Results High AR expression was consistently associated with reduced transcriptome-derived tumor-infiltrating leukocyte scores across multiple ER+/HER2- cohorts. Specifically, signatures associated with cluster of differentiation (CD)-8+ T-cell subsets, dendritic cells, and M1 macrophages were significantly reduced in AR -high tumors, indicating a transcriptionally immune-suppressed tumor microenvironment. In the I-SPY2 cohort, AR -high tumors demonstrated significantly lower pathological complete response rates after neoadjuvant ICI therapy. Furthermore, AR expression showed a predictive performance for ICI response that was superior to that with programmed cell death protein-1 and programmed cell death ligand-1 (area under the curve 0.82 vs. 0.73 and 0.60, respectively). Interestingly, single-cell analysis revealed that AR expression across multiple cell types, including epithelial, endothelial, and myeloid, was associated with reduced ICI responsiveness. Additionally, AR inhibition using enzalutamide was associated with increased signatures associated with CD8+ T cells, dendritic cells, and M1 macrophages. Conclusions These findings suggest that AR expression is associated with an immunosuppressive tumor microenvironment and reduced response to ICIs in ER+/HER2- breast cancer.